On the contrary, the GSE16581 cohort, GSE29621 cohort and GSE24080 cohort showed that when RFC4 expression was elevated, tumour patients would experience longer OS and DSS after ICI treatment (Figure 5E–G), and we found that the UVM immunotherapy cohort in the IMvigor210CoreBiologies using the RFC4 high expression group had a higher immune response than the low‐expressing group (p < 0.001, Figure 5H). Here, RFC4 is linked to neoplasm.